<DOC>
	<DOCNO>NCT00851890</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics antiviral activity ABT-333 ( also know dasabuvir ) treatment-naïve , hepatitis C virus ( HCV ) -infected participant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Antiviral Activity Multiple Doses ABT-333 Alone Combination With Pegylated Interferon ( pegIFN ) Ribavirin ( RBV ) Subjects With Genotype 1 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description>This Phase 2a , blind , randomize , placebo-controlled clinical trial hepatitis C virus ( HCV ) -infected adult 2 plan sequential evaluation , Part 1 Part 2 . The study evaluate safety , tolerability , antiviral activity , pharmacokinetics ABT-333 placebo monotherapy , follow 26 day ABT-333 placebo pegylated interferon a-2a ( pegIFN ) ribavirin ( RBV ) combination therapy . Review safety efficacy Part 1 study show similar response rate across ABT-333 dos Part 2 study perform . The study also assess emergence resistant HCV conjunction kinetics viral load decay rebound treatment-naïve , HCV-infected participant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participant provide write consent . If female , participant postmenopausal surgically sterile . If male , must practice two effective method birth control . Participant hepatitis C virus ( HCV ) genotype 1 HCV ribonucleic acid level &gt; 50,000 IU/mL . Participants must demonstrate chronic hepatitis C infection least 6 month prior study enrollment . Participants must liver biopsy histology consistent HCVinduced liver damage , evidence cirrhosis liver pathology due cause chronic HCV . Condition general good health HCV infection . Participants history thyroid disease must thyroid stimulate hormone ( TSH ) value normal range . No prior history receive therapy HCV infection . Positive test result hepatitis A virus immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus antibody ( HIV Ab ) . Pregnant breastfeeding female male partner woman pregnant . History seizures cancer . History major depressive disorder within 2 year . Any current past history cirrhosis . Any cause liver disease chronic HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>